Nigerian government plans local production of anti-malaria drugs
To further reduce the cost of anti-malaria drug and reduce malaria incidence to the barest minimum, the Nigerian ministry of health says it has plans to produce them in the country. While briefing the press on the 2011 World Malaria Day on Tuesday in Abuja, Onyebuchi Chukwu, the Minister of Health said pharmaceutical industries in Nigeria are not producing the drugs because they are not certified by the World Health Organization to do so.
The Ministry is collaborating with the Bank of Industries on this project. “In collaboration with the Bank of Industry we have started the process of strengthening our pharmaceutical industries to meet WHO certification to produce these drugs locally,” Mr Chukwu said and added that there are issues in their local pharmaceutical sector.
“For instance, when you hear of global fund many of the aid given are in form of supplied commodities but they will only patronise companies that are WHO certified. To have WHO certification there must be minimum standards in place,” he stated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze